Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
TM Maher - Pharmacology & therapeutics, 2015 - Elsevier
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
[引用][C] Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - Pharmacology & Therapeutics, 2015 - cir.nii.ac.jp
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
P Spagnolo, TM Maher, L Richeldi - Pharmacology & Therapeutics, 2015 - europepmc.org
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
[PDF][PDF] Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi… - 2015 - core.ac.uk
1. Introduction 2. Current approach to pharmacological treatment of IPF 3. How we got here
and why did it take so long? 4. What have we learned from negative studies? 5. Recent …
and why did it take so long? 4. What have we learned from negative studies? 5. Recent …
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - folia.unifr.ch
English Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic
interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last …
interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last …
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy.
P Spagnolo, TM Maher, L Richeldi - Pharmacology & therapeutics, 2015 - sonar.ch
English Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic
interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last …
interstitial pneumonias with an estimated 5-year survival of approximately 20%. In the last …
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - Pharmacology & Therapeutics, 2015 - infona.pl
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - PHARMACOLOGY & …, 2015 - research.unipd.it
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
Idiopathic pulmonary fibrosis: recent advances on pharmacological therapy
P Spagnolo, TM Maher, L Richeldi - Pharmacology & …, 2015 - eprints.soton.ac.uk
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
Idiopathic pulmonary fibrosis: Recent advances on pharmacological therapy
P Spagnolo, TM Maher… - Pharmacology & …, 2015 - pubmed.ncbi.nlm.nih.gov
Idiopathic pulmonary fibrosis (IPF) is the most common and lethal of the idiopathic interstitial
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …
pneumonias with an estimated 5-year survival of approximately 20%. In the last two decades …